Proactive Investors
Published Sep 26, 2022 09:22
Emyria capitalises on Cann Group collaboration to progress EMD-003 CBD medicine for mental health
Emyria Ltd’s (ASX:EMD) is set to capitalise on its partnership with Cann Group Ltd (ASX:CAN) (OTCMKTS:CNGGF) (FRA:CVJ) to complete pivotal clinical trials for its EMD-003 CBD medicine targeting mental health and to seek accelerated registration of a unique, low-dose, CBD-only capsule with the Therapeutic Goods Administration (TGA).
Successful registration as a Schedule 3 medicine would result in an over-the-counter (OTC), pharmacist-only CBD medicine.
The company will lead the EMD-003 drug development program using Cann Group’s proprietary Gelpell microsphere technology to register a unique capsule form.
“Partnership accelerates drug development”
Emyria managing director and CEO Dr Michael Winlo said: “This partnership greatly accelerates Emyria’s EMD-003 drug development program by combining Emyria’s unique clinical data and drug development expertise with Cann Group’s best-in-class CBD delivery technology.
“Cann Group’s CBD has already completed robust stability testing as well as Phase 1 clinical trials as required by the TGA.
“This allows us to move straight to pivotal clinical outcomes trials saving significant time and money.”
Advantages of collaboration
The collaboration capitalises on a number of registration milestones already met:
EMD-004 for IBS
Current drug registration programs also include the EMD-004 CBD +/- THC for irritable bowel syndrome (IBS).
The company recently filed a new IP after extensive analysis of its proprietary clinical data collected with consenting patients, who obtained relief from their IBS condition while being treated at Emyria’s wholly-owned, nationwide clinical subsidiary - Emerald Clinics.
There are currently no approved drug treatments for IBS, which affects around 11% of the population globally and is a significant unmet need often associated with greater levels of anxiety and lower quality of life measures.
The company’s patents cover unique dose strengths and formulations, believed to be most effective in treating a range of IBS-related symptoms including:
A large observational study involving IBS patients is currently underway across Emerald Clinics.
Psychedelic-assisted therapy program
The company is also progressing its EMDMA-001 MDMA psychedelic-assisted therapy program with partner Mind Medicine Australia, targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
Pending ethics approval, Emyria will sponsor a major, independently monitored, clinical trial targeting treatment-resistant PTSD with evidence-based MDMA-assisted therapy.
A key priority of this first program is to help evaluate the long-term safety, efficacy and cost benefits of MDMA-assisted psychotherapy.
Such evidence is needed, along with fit-for-purpose clinical infrastructure and trained therapists, to deliver psychedelic-assisted care in a safe, standardised and scalable way.
Pending successful ethics review and the finalisation of all logistics, EMDMA-001 will begin with a Phase II, open-label clinical trial of MDMA-assisted psychotherapy at Emyria’s fit-for-purpose clinic in Melbourne before expanding to other sites.
Emyria’s pipeline and global registration plans.
Milestones for the year ahead
To progress EMD-003 in the next 12 months, the company plans to:
In parallel, Emyria will commence psychedelic-assisted therapy trials, registration trials for EMD-004 and launch registration programs for the US FDA and the European Medicines Agency (EMA).
Read more on Proactive Investors AU
Disclaimer
Written By: Proactive Investors
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.